Health minister holds series of meetings in Geneva
Tribune News Network
Geneva
Minister of Public Health HE Mansoor bin Ebrahim Al Mahmoud held a series of meetings on the sidelines of the ongoing World Health Assembly (WHA) in Geneva.
The minister held separate meetings with Minister of Health of Iraq Dr Saleh Al Hasnawi, Minister of Health of Syria Dr Musab Nazzal Al Ali, Acting Federal Minister of Health of Sudan Dr Haitham Mohamed Ibrahim, Minister of Health and Medical Education of Iran Dr Mohammad Reza Zafarghandi, and Minister of Public Health of Cuba Dr José Ángel Portal Miranda.
The health minister also met separately with Minister of Health of Algeria Abdelhak Saihi, Minister of Health and Social Protection of Morocco Amine Tahraoui, Minister of Public Health of Lebanon Dr Rakan Nassereddine, Minister of Health of Mauritania Abdallahi Wedih, and Minister of Health of Italy Professor Orazio Schillaci.
The minister also met with President of Global Development at the Gates Foundation Dr Chris Elias.
The meetings reviewed bilateral relations between Qatar and each of the respective countries, with a focus on ways to strengthen cooperation in the field of health.
Discussions also covered key issues on the agenda of the ongoing World Health Assembly (WHA) in Geneva, held under the theme 'One World for Health'.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Qatar Tribune
18 hours ago
- Qatar Tribune
Pakistan Healthcare Solutions Conference in Doha fosters bilateral collaboration
Tribune News Network Doha The Embassy of Pakistan in Qatar, in collaboration with Hamad Medical Corporation's (HMC) ITQAN Clinical Simulation and Innovation Centre, successfully hosted the Pakistan Healthcare Solutions Conference on June 2, at the ITQAN Clinical Simulation and Innovation Centre in Doha. The event, organised with the Atlantic International Business Network (AIBN) as the executive partner, aimed to advance a shared vision for healthcare innovation and strengthen Pakistan-Qatar collaboration. The conference was honoured by the presence of Federal Minister for National Health Services, Regulations and Coordination of Pakistan, Syed Mustafa Kamal, as the chief guest from Pakistan, and Assistant Minister for Health Affairs, Ministry of Public Health, Qatar, HE Dr. Salih Al Marri, as the chief guest from Qatar. Ali Al Janahi, HMC acting assistant managing director, Dr. Abdulla Ali Al-Ansari, medical advisor to the managing director of HMC, also attended, highlighting the high-level commitment to bilateral healthcare ties. The event brought together key stakeholders from the medical, pharmaceutical, telehealth, academic, and regulatory sectors of both nations. It provided a platform for government officials, healthcare leaders, innovators, and investors to explore opportunities for cross-border partnerships and advancements in healthcare development. The program commenced with inaugural addresses by Dean of Weill Cornell Medicine-Qatar, Javaid I. Sheikh, M.D., M.B.A., and the Executive Director of the ITQAN Clinical Simulation and Innovation Centre, Dr. Abdulla Ahmad. Their remarks underscored the transformative potential of collaborative efforts in strengthening healthcare systems between Pakistan and Qatar. Keynote presentations were delivered by Lt. Gen. Arshad Naseem HI (M), surgeon general of Pakistan, and Prof. Dr. Ambreen Afzal Ehsan, vice president of the College of Physicians and Surgeons Pakistan. These sessions highlighted Pakistan's advancements in healthcare and set the stage for discussions on bilateral cooperation. Two high-level panel discussions enriched the conference. The first, on Pakistan-Qatar R&D Collaboration, moderated by Rahid Mazhar, featured experts including Prof. Dr. Muhammad Yar, Dr. Ali Raza, Dr. Rayaz Malik, and Dr. Yousuf Al Maslamani. The second, on Emerging Smart Healthcare and Innovation Opportunities, moderated by Dr. Hasham Khan, included Dr. Fatih Mehmet Gul, Dr. Rola Hammoud, Dr. Zahid Ali, Dr. Javaid Sheikh, and Muhammad Irfan, focusing on innovative healthcare technologies. Additional presentations were delivered by Dr. Obaidullah Malik, CEO of the Drug Regulatory Authority of Pakistan (DRAP); Amr Metwally, assistant executive director at ITQAN; Ikram Ul Haq, president of the Sialkot Chamber of Commerce; Muhammad Irfan, CEO of Xeven Solutions; and Tanvir Khan, representing Labware Arabia. These talks showcased innovations in regulatory frameworks, medical technology, and industry partnerships. An exhibition featured stalls from leading companies such as Allison, Labware, and others, displaying advancements in medical devices, laboratory technologies, and AI-powered solutions. This interactive platform facilitated knowledge exchange and explored potential avenues for future collaboration. The conference concluded with remarks by Hafiz Muhammad Talha, CEO of AIBN and managing director of Metas Qatar, followed by a closing address by Ambassador of Pakistan to Qatar HE Muhammad Aamer. The ambassador reaffirmed the Embassy's commitment to fostering enduring healthcare partnerships between Pakistan and Qatar.
Qatar Tribune
2 days ago
- Qatar Tribune
Sheikha Moza opens HSCT ward at Sidra Medicine
Tribune News Network Doha HH Sheikha Moza bint Nasser, Chairperson of Qatar Foundation for Education, Science and Community Development, officially inaugurated the new paediatric Hematopoietic Stem Cell Transplant (HSCT) ward at Sidra Medicine, a Qatar Foundation entity. The new ward is dedicated to treating children with blood disorders, immune system diseases, and genetic conditions. During the visit, Sheikha Mozatoured the facility, engaged with clinical teams, and received an overview of the HSCT programme's role in advancing care and stem cell and gene therapies for children in Qatar and the region. Sheikha Moza was accompanied by Minister of Public Health HE Mansoor bin Ebrahim bin Saad Al Mahmoud, members of Sidra Medicine's Board of Directors and senior leadership, including Dr Iyabo Tinubu-Karch, Chief Executive Officer and Prof Ibrahim Janahi, Chief Medical Officer. The HSCT ward is a core part of Sidra Medicine's HSCT Programme, using curative therapies to provide life-saving care and treatment for children with a range of blood diseases and cancers. This includes malignant and non-malignant conditions such as leukemia, lymphoma, thalassemia, sickle cell disease, immune deficiencies, and metabolic disorders. HSCT also known as bone marrow transplant, replaces diseased or damaged bone marrow with healthy stem cells from the patient (autologous) or a donor (allogeneic). Dr Iyabo Tinubu-Karch, CEO of Sidra Medicine, said: 'The opening of our new pediatric Hematopoietic Stem Cell Transplant Ward, the first of its kind in the country, marks a major step in expanding access to life-saving care for children in Qatar and the region. As the HSCT program grows, it will play a vital role in reducing the need for outbound referrals and in positioning Qatar as a center of excellence for pediatric cell and gene therapies. This is about building sustainable, high-quality care close to home for our patients and their families.' Prof. Ibrahim Janahi, Chief Medical Officer at Sidra Medicine, said: 'The launch of the HSCT Ward reflects our commitment to supporting the Qatar National Vision 2030. It strengthens the foundation of a knowledge-based economy by building national expertise in precision and regenerative medicine. Our goal is to ensure that every child in Qatar can access the best possible treatment, close to home and grounded in clinical excellence.' Managed by the Hematology and Oncology Division at Sidra Medicine, the new ward is designed exclusively for pediatric patients under the age of 18. It is divided into two main sections - one section for children undergoing HSCT and the other for patients with complex hematology-oncology diagnoses such as cancer, that require intensive chemotherapy and inpatient care. With an initial capacity of 20 beds, the new pediatric HSCT ward integrates cutting-edge infrastructure, including high-level isolation facilities that meet international infection control standards. It is scheduled to receive patients for autologous transplants in late June of 2025 with preparations underway to care for inpatient children who will undergo allogeneic transplants, at a later stage. Dr Ayman Saleh, Division Chief of Pediatric Hematology-Oncology & Hematopoietic Stem Cell Transplant at Sidra Medicine said: 'Our HSCT program brings together key specialties to deliver advanced and curative care for children with complex conditions. With four autologous procedures successfully completed and plans underway to offer allogeneic transplants in the near future, we are building a strong foundation for pediatric cellular therapy in Qatar. This service is a testament to the pioneering and family-centered care and cure approach that we offer to all our patients.' In addition to treating patients with various blood diseases and cancers, the HSCT program at Sidra Medicine is the core part of its precision medicine strategy to facilitate genomic research programs for pediatric autoimmune disorders, genetic and rare diseases. Sidra Medicine's HSCT program is further enhanced by a Good Manufacturing Practice (GMP)-qualified laboratory team operating under the Advanced Cell Therapy Core (ACTC). The ACTC manages the processing and cryopreservation of hematopoietic stem cells and is currently working toward Sidra Medicine's qualification as a treatment center for Casgevy, a gene therapy for thalassemia and sickle cell disease. Dr Chiara Cugno, Director of the Advanced Cell Therapy Core and GMP Facility at Sidra Medicine said: 'Our GMP-qualified laboratory is a key enabler in delivering safe and effective cellular therapies. By maintaining the highest standards in cell processing and cryopreservation, we are supporting precision treatments for children with cancer, blood, and immunologic disorders. It is an essential part of ensuring every child receives the most personalized care possible.' All HSCT program services will be open to both local and international patients, with more than 50 children currently awaiting transplantation in Qatar. Future phases for the HSCT program include scaling allogeneic transplant capacity and introducing CAR-T cell and gene therapies. The HSCT program includes a multidisciplinary team of specialized physicians, apheresis-trained staff, dedicated HSCT nurses, and allied health professionals. The Sidra Medicine care team also involves experts in immunology, infectious diseases, radiology, psychology, pharmacy, nutrition, child life, and social work. The integrated approach ensures comprehensive and patient-centered care throughout the transplant journey. Before a transplant, every child will go through a detailed evaluation at Sidra Medicine's outpatient clinic to ensure they are ready for the procedure. Once admitted, the children will undergo conditioning chemotherapy to prepare their bodies for the stem cell infusion. They will then be monitored very closely during the aplasia phase, when their immune system is at its weakest. Most patients will stay at the hospital for about 30 to 40 days. Following discharge, they will continue their care through regular follow-ups in an outpatient setting. In addition to medical and nursing care, Sidra Medicine offers support services for patients and families, including social work, clinical nurse specialists, and case management. While formal support groups are under development, ongoing engagement with families is embedded throughout the care process.
Qatar Tribune
2 days ago
- Qatar Tribune
Spotlight on SidraMedicine's Stem Cell Transplant Ward
Tribune News Network Doha The new Paediatric Hematopoietic Stem Cell Transplant (HSCT) Ward at Sidra Medicine represents a major advancement in its commitment to deliver state-of-the-art, lifesaving care for children with cancer, blood disorders, immune deficiencies, and other complex conditions. As part of Sidra Medicine's comprehensive Paediatric Hematology—Oncology, and HSCT Programme, the ward is uniquely equipped to provide curative therapy through cellular and gene-based treatment approaches. This initiative positions Sidra Medicine as a national and regional leader in paediatric stem cell transplantation and personalized medicine. 1. What is the purpose of the new paediatric HSCT Ward at Sidra Medicine? The new paediatric HSCT Ward is designed to treat children with life-threatening cancer, blood, immune, and genetic disorders. It is a core part of Sidra Medicine's HSCT Programme using curative therapy to provide life-saving treatment for children. is HSCT and how does it work? HSCT (Hematopoietic Stem Cell Transplantation), also known as bone marrow transplant, replaces diseased or damaged bone marrow with healthy stem cells from the patient (autologous) or a donor (allogeneic). It is currently the only curative treatment for many congenital and acquired otherwise fatal and acquired fatal paediatric diseases. The procedure is at the forefront of personalised medicine and plays a vital role in the development of advanced cell and gene therapies. 3. Why is the paediatric HSCT ward being opened? To address the growing demand for paediatric transplant services, eliminate the need for families to travel abroad, and enhance our national capability in advanced cellular therapy. conditions will be treated at theHSCT Ward? The HSCT ward will serve paediatric patients with a range of malignant and non-malignant conditions, including leukemia, lymphoma, solid tumours, thalassemia, sickle cell disease, primary immune deficiencies, metabolic diseases, and certain autoimmune and genetic disorders. many beds are in the HSCT Ward? The paediatric hematology-oncology and HSCT Ward has a 20-bed capacity. It is divided into two main sections: One section is dedicated to pediatric patients undergoing HSCT (bone marrow transplant), and the other for patients with complex hemato-oncology diagnoses, such as paediatric cancer, who are receiving chemotherapy or inpatient care for treatment-related complications. Note that HSCT is a medical—not surgical—procedure, and no surgeries take place in the HSCT ward. will the paediatric HSCT ward open? The paediatric HSCT ward is scheduled to receive patients for autologous transplants in late June of 2025 with preparations underway to care for inpatient children who will undergo allogeneic transplants at a later stage. is eligible for treatment? The ward is exclusively for paediatric patients under the age of 18. It serves both local and international patients in need of HSCT or inpatient hematology-oncology care. is the HSCT Programme about? The HSCT programme at Sidra Medicine is part of a precision medicine strategy to treat patients with various blood diseases and cancers including sickle cell disease, thalassemia, leukemia, lymphoma, solid tumors. In addition, the programme includes the treatment of primary immune deficiencies, metabolic diseases, and certain genetic and autoimmune disorders. makes this programme unique in Qatar? This is the first dedicated paediatric HSCT programme in the country, reducing the need for children to travel abroad for transplant services. The programme also integrates cutting-edge research, cell therapy, and gene therapy capabilities. 10. What are the safety and infection control measures in place? The unit adheres to the highest international infection control standards, including high-level HEPA-filtered, positive pressure isolation rooms to protect patients during the vulnerable aplasia period when the immune system is suppressed. 11. How many children are currently awaiting HSCT in Qatar? More than 50 children are currently on the transplant waitlist, highlighting the urgent need for this new facility. Sidra Medicine treat international patients? Yes, our services are open to eligible international paediatric patients and align with our vision to be a regional centre of excellence in paediatric cell and gene therapy.
